Longgang District People's Hospital of Shenzhen
13
5
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
Role: collaborator
Impact of Computer-aided Detection System on the Proximal Adenoma Miss Rate
Role: collaborator
Research on Identifying and Treatment Prognosis of Chronic Rhinosinusitis Based on Image and Sequencing Data
Role: collaborator
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
Role: collaborator
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
Role: collaborator
Fluid Responsiveness and Venous Congestion Evolution During Volume Expansion
Role: collaborator
Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Role: collaborator
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
Role: collaborator
Study on the Effect of 3T Pu'er Tea in Regulating Glucose and Lipid Metabolism
Role: lead
Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Role: collaborator
SNP-based Prediction of Recurrence Risk in Kidney Stone Patients
Role: collaborator
Bovine Colostrum for Preterm Newborns
Role: collaborator
Nilotinib for First-line Newly Diagnosed CML-CP Patients
Role: collaborator
All 13 trials loaded